Keywords: عوامل ضد انعقادی; Epithelial ovarian cancer; Antiangiogenic agents; Maintenance therapy; Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors; PARPi;
مقالات ISI عوامل ضد انعقادی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: عوامل ضد انعقادی; Antiangiogenic agents; Breast cancer; Comprehensive; OmniseqSM; Palbociclib;
Keywords: عوامل ضد انعقادی; TACE; Transarterial Chemoembolization; cTACE; conventional Transarterial Chemoembolization; HCC; hepatocellular carcinoma; EASL; European Association for the Study of the Liver Guidelines; qEASL; 3D quantitative European Association for the Study of the L
Keywords: عوامل ضد انعقادی; Antiangiogenic agents; endometriosis; future medical therapy; immunomodulators;
Keywords: عوامل ضد انعقادی; ZTJOCDUDIVQZDR-DVNQVLBESA-N; WFUYFBBPPFFWLK-WVZVNDETSA-N; RWTLHADKCUBLTO-DKGAOUFQSA-N; RGPIPIBZRORUEM-ZWXIRZRQSA-N; VEPJZBUPJUWVJA-UHFFFAOYSA-N; ZWFOOMQCYIGZBE-ZOBUZTSGSA-N; RBXKAWIISCLQSK-LYDQXETESA-N; NGDOHYUFIMQHRU-SZKYPABLSA-N; QPXDJAQCABFFAR-UHFFFAOY
Keywords: عوامل ضد انعقادی; adverse sequelae; alopecia; antiangiogenic agents; anticancer; BCR-ABL; bevacizumab; cancer treatment; canertinib; cetuximab; chemotherapy; cutaneous adverse effects; dasatinib; dermatologic toxicities; disturbed wound healing; drug eruption; drug rash; d
Keywords: عوامل ضد انعقادی; Antiangiogenic agents; Metastatic renal cells cancer; Complete response; Sunitinib; Sorafenib; Pazopanib; Bevacizumab; Cytokines; Interferon;
Keywords: عوامل ضد انعقادی; Epithelial ovarian cancer; Biomarkers; Antiangiogenic agents;
Keywords: عوامل ضد انعقادی; Angiogenesis; Antiangiogenic agents; Angiogenic cytokines/peptides; EC; endothelial cells; VEGF; vascular endothelial growth factor; VEGF Receptor; VEGFR; FGF; fibroblast growth factor; EGF; epidermal growth factor; epidermal growth factor receptor; EGFR;
The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
Keywords: عوامل ضد انعقادی; Circulating endothelial cells; Endothelial colony forming cells; Renal cell carcinoma; Resistance; Antiangiogenic agents; mTOR inhibitors;
Devastadora complicación tras tratamiento con aflibercept
Keywords: عوامل ضد انعقادی; Perforación intestinal; Aflibercept; Neoplasia colorrectal; Agentes antiangiogénicos; Intestinal perforation; Aflibercept; Colorectal neoplasms; Antiangiogenic agents;
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents
Keywords: عوامل ضد انعقادی; Multiple receptor tyrosine kinase inhibitors; Antiangiogenic agents; Pyrimido[4,5-b]indole synthesis; Thymidylate synthase inhibitors; Combination chemotherapeutic potential in single agents; RTK; receptor tyrosine kinases; VEGF; vascular endothelial grow
Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient
Keywords: عوامل ضد انعقادی; Medication-related osteonecrosis of the jaw; Renal cell carcinoma; Antiangiogenic agents;
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors
Keywords: عوامل ضد انعقادی; Medication-related osteonecrosis of the jaws; Frequency; Risk factors; Zolendronate; Oral bisphosphonates; Antiresorptive medications; Antiangiogenic agents;
Antiangiogenic Agents and the Skin: Cutaneous Adverse Effects of Sorafenib, Sunitinib, and Bevacizumab
Keywords: عوامل ضد انعقادی; Angiogenesis; Antiangiogenic agents; Cutaneous adverse effects; Sorafenib; Sunitinib; BevacizumabAngiogénesis; Antiangiogénesis; Efectos cutáneos adversos; Sorafenib; Sunitinib; Bevacizumab
Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab
Keywords: عوامل ضد انعقادی; Angiogénesis; Antiangiogénesis; Efectos cutáneos adversos; Sorafenib; Sunitinib; BevacizumabAngiogenesis; Antiangiogenic agents; Cutaneous adverse effects; Sorafenib; Sunitinib; Bevacizumab
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models
Keywords: عوامل ضد انعقادی; Heparanase inhibitor; SST0001; Antiangiogenic agents; Pediatric sarcomas; Antitumor activity
Combination of vascular disrupting agents and ionizing radiation
Keywords: عوامل ضد انعقادی; Vascular disrupting agents; Radiotherapy; CA-4-P; Tubulin binding agents; Antiangiogenic agents; Preclinical rationale
N4-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: Design, synthesis, and in vivo evaluation
Keywords: عوامل ضد انعقادی; ATP; adenosine 5â²triphosphate; VEGF; vascular endothelial growth factor; EGF; epidermal growth factor; PDGF; platelet derived growth factor; RTK; receptor tyrosine kinase; KDR; kinase insert domain receptor; VEGFR-2; vascular endothelial growth factor r
Safety Profile and Tolerability of Antiangiogenic Agents in Non–Small-Cell Lung Cancer
Keywords: عوامل ضد انعقادی; Antiangiogenic agents; Bevacizumab; Non–small-cell lung cancer; Safety; Tolerability
Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy
Keywords: عوامل ضد انعقادی; Non-small cell lung cancer; Targeted agents; Chemoradiotherapy; EGFR inhibitors; Antiangiogenic agents; Phase I trials; Preclinical models; Radiotherapy; Combined modality treatment
Thérapies ciblées et radiothérapie dans les cancers bronchiques non à petites cellules
Keywords: عوامل ضد انعقادی; Non small cell lung carcinoma; Antiangiogenic agents; Concomitant radiochemotherapy; EGFR; MTOR; Histone deacetylase; Aurora kinase; Cancer stem cellsCarcinome bronchique non à petites cellules; Antiangiogéniques; Chimioradiothérapie concomitante; EGFR; M
A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
Keywords: عوامل ضد انعقادی; Lung cancer; Non-small cell; Antiangiogenic agents
Chimiothérapie et traitements ciblés des glioblastomes
Keywords: عوامل ضد انعقادی; Chemotherapy; Antiangiogenic agents; Targeted therapies; Glioblastoma; Chimiothérapie; Antiangiogéniques; Traitements ciblés; Glioblastome;
Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review
Keywords: عوامل ضد انعقادی; Lung cancer; Antiangiogenic agents; Vascular disrupting Agents
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents1
Keywords: عوامل ضد انعقادی; RTKs; receptor tyrosine kinases; PDGFR; platelet-derived growth factor receptor; FGFR; fibroblast growth factor receptor; IGFR; insulin growth factor receptor; VEGFR; vascular endothelial growth factor receptor; EGFR; epidermal growth factor receptor; CAM
Antiangiogenic strategies in breast cancer management
Keywords: عوامل ضد انعقادی; Breast cancer angiogenesis; Antiangiogenic agents; Monoclonal antibodies; Tyrosin kinase inhibitors; Metronomic chemotherapy; Bisphosphonates; Hormonal therapy; COX-2 inhibitors
Angiogenesis in cutaneous disease: Part II
Keywords: عوامل ضد انعقادی; angiogenesis; antiangiogenic agents; dermatology
Angiogenesis in cutaneous disease: Part I
Keywords: عوامل ضد انعقادی; angiogenesis; antiangiogenic agents; dermatology
Design of antiangiogenic hypoxic cell radiosensitizers: 2-Nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety
Keywords: عوامل ضد انعقادی; Hypoxic cell radiosensitizers; Antiangiogenic agents; 2-Aminomethylene-4-cyclopentene-1,3-dione; Protein tyrosine kinase
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents
Keywords: عوامل ضد انعقادی; Multiple receptor; Tyrosine kinase inhibitors; Antiangiogenic agents
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs
Keywords: عوامل ضد انعقادی; MMP-inhibitors; MMP-2/MT1-MMP selective inhibitors; Antiangiogenic agents; Twin hydroxamic acids; MMPi; Arylsulfonamido-based hydroxamate
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP
Keywords: عوامل ضد انعقادی; MMP-inhibitors; MMP-2/MT1-MMP selective inhibitors; Antiangiogenic agents;
The use of subretinal triamcinolone acetonide in the management of neovascular age-related macular degeneration: a pilot study
Keywords: عوامل ضد انعقادی; age-related macular degeneration; antiangiogenic agents; choroidal neovascularization; subretinal neovascularization; submacular surgery; subretinal triamcinolone; triamcinolone;